Table 1.
Baseline characteristics of cohorts 1 and 2
| Baseline Characteristics | Cohort 1 | Cohort 2 | ||||
|---|---|---|---|---|---|---|
| Control | UC | CD | Control | UC | CD | |
| LL-37 Range (ng/mL) | 23–79 | 12–245 | 13–94 | 26–70 | 21–167 | 13–282 |
| Age at Collection (mean ± SEM) | 46 ± 2 | 40 ± 2 | 35 ± 2 | 43 ± 3 | 37 ± 1 | 38 ± 2 |
| Age at diagnosis (mean ± SEM) | 35 ± 2 | 30 ± 2 | 28 ± 1 | 25 ± 1 | ||
| Duration of Disease in Years (mean ± SEM) | 6 ± 1 | 6 ± 1 | 8 ± 1 | 13 ± 2 | ||
| Gender (% Male) | 42% | 35% | 25% | 40% | 56% | 52% |
| Percentage of patients who used biologics | 13% | 38% | 16% | 45% | ||
| Percentage of patients who used steroids | 17% | 52% | 32% | 30% | ||
| Percentage of patients who used immunomodulators | 9% | 14% | 21% | 38% | ||
| Percentage of patients who used 5-aminosalicyclic acid (5-ASA) | 74% | 24% | 58% | 24% | ||
| Percentage of Current Smoker (%) | 20% | 13% | 21% | 20% | 7% | 12% |
| C-reactive protein (CRP) Levels (mg/L) (mean ± SEM) | 1.18 ± 0.42 | 4.77 ± 1.43 | 0.75 ± 0.16 | 1.59 ± 0.39 | ||
| UC Partial Mayo Score (mean ± SEM) | 2.09 ± 0.47 | 3.04 ± 0.29 | ||||
| UC Mayo Endoscopic Score (mean ± SEM) | 1.64 ± 0.19 | 1.13 ± 0.14 | ||||
| UC Partial Mayo Score 6–18 months later (mean ± SEM) | 2.40 ± 0.52 | 1.59 ± 0.28 | ||||
| Montreal Classification of UC: | ||||||
| UC ulcerative proctitis E1 (%) | 38% | 16% | ||||
| UC left sided colitis E2 (%) | 24% | 59% | ||||
| UC pancolitis E3 (%) | 29% | 22% | ||||
| CD Harvey Bradshaw Index (mean ± SEM) | 3.67 ± 0.77 | 4.22 ± 0.44 | ||||
| CD Harvey Bradshaw Index 6–18 months later (mean ± SEM) | 2.54 ± 0.65 | 1.38 ± 0.26 | ||||
| Montreal Classification of CD: | ||||||
| CD Age at diagnosis less than 16 years A1 % | 12% | 27% | ||||
| CD Age at diagnosis 17–40 years A2 % | 59% | 60% | ||||
| CD Age at diagnosis over 40 years A3 % | 29% | 12% | ||||
| CD ileal L1 (%) | 56% | 23% | ||||
| CD colonic L2 (%) | 6% | 15% | ||||
| CD ilealcolonic L3 (%) | 38% | 63% | ||||
| CD isolated upper digestive tract L4 (%) | 13% | 7% | ||||
| CD non-stricturing, non-penetrating B1 (%) | 43% | 57% | ||||
| CD stricturing B2 (%) | 50% | 24% | ||||
| CD penetrating B3 (%) | 11% | 27% | ||||
| CD perianal disease P (%) | 11% | 0% | ||||
| 50 | 23 | 28 | 20 | 57 | 67 | |